Open in App
  • Local
  • U.S.
  • Election
  • Politics
  • Crime
  • Sports
  • Lifestyle
  • Education
  • Real Estate
  • Newsletter
  • targetedonc.com

    Second-line Treatment for RS-negative Lower-Risk MDS: Choosing Between EMA and Telomerase Inhibitor Options

    By Mikkael Sekeres, MD,

    2 days ago
    Comments / 0
    Add a Comment
    YOU MAY ALSO LIKE
    Most Popular newsMost Popular
    verywellhealth.com29 days ago

    Comments / 0